{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:32:45Z","timestamp":1787016765415,"version":"build-2736575974"},"reference-count":48,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>\n                    Clinical susceptibility breakpoints against\n                    <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n                    and\n                    <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n                    for the ceftazidime-avibactam dosage regimen of 2,000\/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, \u22648 mg\/liter) and resistant (MIC, &gt;8 mg\/liter). The key supportive data from pharmacokinetic\/pharmacodynamic analyses,\n                    <jats:italic>in vitro<\/jats:italic>\n                    surveillance, including molecular understanding of relevant resistance mechanisms, and efficacy in regulatory clinical trials are collated and analyzed here.\n                  <\/jats:p>","DOI":"10.1128\/aac.02590-17","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T10:08:50Z","timestamp":1532513330000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa"],"prefix":"10.1128","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3305-6388","authenticated-orcid":false,"given":"Wright W.","family":"Nichols","sequence":"first","affiliation":[{"name":"AstraZeneca, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[{"name":"AstraZeneca, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Newell","sequence":"additional","affiliation":[{"name":"AstraZeneca, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Broadhurst","sequence":"additional","affiliation":[{"name":"AstraZeneca, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Wardman","sequence":"additional","affiliation":[{"name":"AstraZeneca, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merran","family":"MacPherson","sequence":"additional","affiliation":[{"name":"Wright Dose Ltd., Altrincham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Yates","sequence":"additional","affiliation":[{"name":"AstraZeneca, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Riccobene","sequence":"additional","affiliation":[{"name":"Allergan plc, Madison, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Critchley","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-4816","authenticated-orcid":false,"given":"Shampa","family":"Das","sequence":"additional","affiliation":[{"name":"AstraZeneca, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw239"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03042-15"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02286-15"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00220-16"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02841-15"},{"key":"e_1_3_2_8_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 23rd informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2013","unstructured":"Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_9_2","volume-title":"Summary of product characteristics: Zavicefta","author":"Pfizer","year":"2018","unstructured":"Pfizer. 2018. Summary of product characteristics: Zavicefta. Pfizer, New York, NY. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004027\/WC500210234.pdf."},{"key":"e_1_3_2_10_2","volume-title":"AVYCAZ (ceftazidime-avibactam) for injection, for intravenous use: prescribing information","author":"Allergan","year":"2018","unstructured":"Allergan. 2018. AVYCAZ (ceftazidime-avibactam) for injection, for intravenous use: prescribing information. Allergan, Dublin, Ireland. http:\/\/pi.actavis.com\/data_stream.asp?product_group=1957&p=pi&language=E."},{"key":"e_1_3_2_11_2","volume-title":"Performance standards for antimicrobial susceptibility testing; 28th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; 28th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03752.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-06"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit017"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00022-5"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01265.x"},{"key":"e_1_3_2_17_2","first-page":"dks468","article-title":"Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia","volume":"68","author":"Muller AE","year":"2012","unstructured":"Muller AE, Punt N, Mouton JW. 2012. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother 68:dks468.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01463-13"},{"key":"e_1_3_2_19_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2010. Ceftazidime: rationale for the EUCAST clinical breakpoints version 1.0. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Ceftazidime_Rationale_Document_1.0_2010Nov.pdf."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/52.6_Suppl_2.S23"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02446-17"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01269-15"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00080-14"},{"key":"e_1_3_2_24_2","unstructured":"Carrothers TJ Green M Chiu J Riccobene T Lovern M. 2014. Population pharmacokinetic modeling of combination treatment of intravenous ceftazidime and avibactam abstr T-071. Abstr 5th Am Conf Pharmacometrics Las Vegas NV. http:\/\/www.go-acop.org\/assets\/Legacy_ACOPs\/ACOP5\/Poster_Abstracts\/t-071.pdf."},{"key":"e_1_3_2_25_2","volume-title":"PK\/PD target attainment analyses and assessment of dose adjustments for renal insufficiency for ceftazidime-avibactam (CAZ-AVI) in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) or nosocomial pneumonia (NP), abstr 2459","author":"Li J","year":"2015","unstructured":"Li J, Zhou D, Nichols WW, Al-Huniti N, Lovern MR, Green ML, Chiu JS, Riccobene TA, Carrothers TJ, Das S. 2015. PK\/PD target attainment analyses and assessment of dose adjustments for renal insufficiency for ceftazidime-avibactam (CAZ-AVI) in patients with complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) or nosocomial pneumonia (NP), abstr 2459. Abstr Am Assoc Pharmaceutical Sci (AAPS) Annu Meet, Orlando, FL."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12585"},{"key":"e_1_3_2_27_2","volume-title":"ASM Microbe","author":"Das S","year":"2016","unstructured":"Das S, Wright JG, Riccobene T, Macpherson M, Carrothers TJ, Lovern M. 2016. Comparison of ceftazidime-avibactam (CAZ-AVI) Exposure and PK\/PD target attainment (TA) across patient subgroups, abstr MONDAY-500. ASM Microbe, 16 to 20 June 2016, Boston, MA. http:\/\/www.abstractsonline.com\/pp8\/#!\/4060\/presentation\/18014."},{"key":"e_1_3_2_28_2","unstructured":"European Medicines Agency. 2016. Assessment report: Zavicefta. European Medicines Agency London United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004027\/WC500210236.pdf."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03056-15"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2016.036"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-16"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01045-17"},{"key":"e_1_3_2_33_2","unstructured":"Kazmierczak K Estabrook M de Jonge B Stone G Sahm D. 2017. Activity of ceftazidime-avibactam against isolates of Enterobacteriaceae and P. aeruginosa collected in Europe as part of the INFORM global surveillance program 2015 abstr P1295. Abstr 27th Eur Congr Clin Microbiol Infect Dis (ECCMID) Vienna Austria. https:\/\/www.escmid.org\/escmid_publications\/escmid_elibrary\/material\/?mid=41547."},{"key":"e_1_3_2_34_2","first-page":"S379","article-title":"Activity of ceftazidime-avibactam against respiratory isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin America as part of the INFORM global surveillance program, 2014-2016","volume":"4","author":"Kazmierczak K","year":"2017","unstructured":"Kazmierczak K, Estabrook M, Stone G, Sahm D. 2017. Activity of ceftazidime-avibactam against respiratory isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin America as part of the INFORM global surveillance program, 2014-2016. Open Forum Infect Dis 4:S379.","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_2_35_2","first-page":"S379","article-title":"Activity of ceftazidime-avibactam against respiratory isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia\/Pacific as part of the INFORM global surveillance program, 2014\u20132016","volume":"4","author":"Kazmierczak K","year":"2017","unstructured":"Kazmierczak K, Wise M, Stone G, Sahm D. 2017. Activity of ceftazidime-avibactam against respiratory isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia\/Pacific as part of the INFORM global surveillance program, 2014\u20132016. Open Forum Infect Dis 4:S379\u2013S380.","journal-title":"Open Forum Infect Dis"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv145"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01896-13"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70168-3"},{"key":"e_1_3_2_39_2","unstructured":"Castanheira M Farrell SE Kozlov RS Stefaniuk E Tsakris A Goossens H Jones RN. 2013. Beta-lactamase production among ceftazidime-resistant Pseudomonas aeruginosa from five European countries: high prevalence of oxacillinases and VIM enzymes in the SENTRY Programme abstr P1339. Abstr 23rd Eur Congr Clin Microbiol Infect Dis (ECCMID) Berlin Germany. https:\/\/www.escmid.org\/escmid_publications\/escmid_elibrary\/material\/?mid=6997."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks523"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw133"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw378"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.01.010"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30747-8"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000206"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1310"},{"key":"e_1_3_2_48_2","volume-title":"Ceftazidime-avibactam: use of a predictor panel to evaluate and optimize avibactam concentrations for in vitro susceptibility testing, abstr P1290","author":"Huband M","year":"2015","unstructured":"Huband M, Nichols W, Otterson LG, Stone G, Bradford P. 2015. Ceftazidime-avibactam: use of a predictor panel to evaluate and optimize avibactam concentrations for in vitro susceptibility testing, abstr P1290. Abstr 25th Eur Congr Clin Microbiol Infect Dis (ECCMID), Copenhagen, Denmark. https:\/\/www.escmid.org\/escmid_publications\/escmid_elibrary\/material\/?mid=23758."},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00223-18"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02590-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02590-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:18:21Z","timestamp":1645460301000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02590-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1128\/AAC.02590-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02590-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"2018-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02590-17"}}